Memory T Cells Targeting Oncogenic Mutations Detected in Peripheral Blood of Epithelial Cancer Patients

Overview

Journal Nat Commun

Specialty Biology

Date 2019 Jan 27

PMID 30683863

Citations 98

Authors

Gal Cafri

Rami Yossef

Anna Pasetto

Drew C Deniger

Yong-Chen Lu

Maria Parkhurst

Jared J Gartner

Li Jia

Satyajit Ray

Lien T Ngo

Mohammad Jafferji

Abraham Sachs

Todd Prickett

Paul F Robbins

Steven A Rosenberg

Affiliations

Soon will be listed here.

Abstract

T cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor infiltrating lymphocytes, but whether such cells can be detected in the peripheral blood of patients with the common metastatic epithelial cancer patients is unknown. Using a highly sensitive in vitro stimulation and cell enrichment of peripheral memory T cells from six metastatic cancer patients, we identified and isolated CD4, and CD8 memory T cells targeting the mutated KRAS and KRAS variants, respectively, in three patients. In an additional two metastatic colon cancer patients, we detected CD8 neoantigen-specific cells targeting the mutated SMAD5 and MUC4 proteins. Therefore, memory T cells targeting unique as well as shared somatic mutations can be detected in the peripheral blood of epithelial cancer patients and can potentially be used for the development of effective personalized T cell-based cancer immunotherapy across multiple patients.

Citing Articles

Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site.

Roberti M, Charoentong P, Lyu Y, Meyer M, Eichmuller S, Schmidt P Oncoimmunology. 2025; 14(1):2457793.

PMID: 39902862 PMC: 11796541. DOI: 10.1080/2162402X.2025.2457793.

Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.

Xu X, Guo S, Gu H, Cha Z, Shi X, Yin X JCI Insight. 2025; 10(2).

PMID: 39846249 PMC: 11790028. DOI: 10.1172/jci.insight.181873.

Utilization of primary tumor samples for cancer neoantigen discovery.

Leko V, Groh E, Levi S, Copeland A, White B, Gasmi B J Immunother Cancer. 2025; 13(1.

PMID: 39800378 PMC: 11748769. DOI: 10.1136/jitc-2024-010993.

Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies.

Damiani D, Tiribelli M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770471 PMC: 11728840. DOI: 10.3390/ph17121629.

A dendritic cell vaccine for both vaccination and neoantigen-reactive T cell preparation for cancer immunotherapy in mice.

Li Q, Zeng H, Liu T, Wang P, Zhang R, Zhao B Nat Commun. 2024; 15(1):10419.

PMID: 39613742 PMC: 11607313. DOI: 10.1038/s41467-024-54650-y.

References

Deniger D, Pasetto A, Robbins P, Gartner J, Prickett T, Paria B . T-cell Responses to "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. Clin Cancer Res. 2018; 24(22):5562-5573. PMC: 6239943. DOI: 10.1158/1078-0432.CCR-18-0573. View

Gedde-Dahl 3rd T, Spurkland A, Fossum B, Wittinghofer A, Thorsby E, Gaudernack G . T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. Eur J Immunol. 1994; 24(2):410-4. DOI: 10.1002/eji.1830240221. View

Tran E, Ahmadzadeh M, Lu Y, Gros A, Turcotte S, Robbins P . Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015; 350(6266):1387-90. PMC: 7445892. DOI: 10.1126/science.aad1253. View

Cohen C, Gartner J, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky V . Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015; 125(10):3981-91. PMC: 4607110. DOI: 10.1172/JCI82416. View

Li Y, Yee C . IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood. 2007; 111(1):229-35. PMC: 2200808. DOI: 10.1182/blood-2007-05-089375. View

Wang Q, Yu Z, Griffith K, Hanada K, Restifo N, Yang J . Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunol Res. 2015; 4(3):204-14. PMC: 4775432. DOI: 10.1158/2326-6066.CIR-15-0188. View

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

Tran E, Robbins P, Rosenberg S . 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017; 18(3):255-262. PMC: 6295671. DOI: 10.1038/ni.3682. View

Stevanovic S, Pasetto A, Helman S, Gartner J, Prickett T, Howie B . Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017; 356(6334):200-205. PMC: 6295311. DOI: 10.1126/science.aak9510. View

10.

Bolger A, Lohse M, Usadel B . Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014; 30(15):2114-20. PMC: 4103590. DOI: 10.1093/bioinformatics/btu170. View

11.

Assadipour Y, Zacharakis N, Crystal J, Prickett T, Gartner J, Somerville R . Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2017; 23(15):4347-4353. PMC: 6348475. DOI: 10.1158/1078-0432.CCR-16-1423. View

12.

Gros A, Robbins P, Yao X, Li Y, Turcotte S, Tran E . PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014; 124(5):2246-59. PMC: 4001555. DOI: 10.1172/JCI73639. View

13.

Russo A, Borger D, Szymonifka J, Ryan D, Wo J, Blaszkowsky L . Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014; 120(10):1482-90. PMC: 4327902. DOI: 10.1002/cncr.28599. View

14.

Inozume T, Hanada K, Wang Q, Ahmadzadeh M, Wunderlich J, Rosenberg S . Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010; 33(9):956-64. PMC: 2980947. DOI: 10.1097/CJI.0b013e3181fad2b0. View

15.

Fossum B, Olsen A, Thorsby E, Gaudernack G . CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13-->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother. 1995; 40(3):165-72. PMC: 11037639. DOI: 10.1007/BF01517348. View

16.

Fossum B, Gedde-Dahl 3rd T, Breivik J, Eriksen J, Spurkland A, Thorsby E . p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp). Int J Cancer. 1994; 56(1):40-5. DOI: 10.1002/ijc.2910560108. View

17.

Carbone D, Ciernik I, Kelley M, Smith M, Nadaf S, Kavanaugh D . Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol. 2005; 23(22):5099-107. DOI: 10.1200/JCO.2005.03.158. View

18.

Pasetto A, Gros A, Robbins P, Deniger D, Prickett T, Matus-Nicodemos R . Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor. Cancer Immunol Res. 2016; 4(9):734-43. PMC: 5010958. DOI: 10.1158/2326-6066.CIR-16-0001. View

19.

Tran E, Robbins P, Lu Y, Prickett T, Gartner J, Jia L . T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016; 375(23):2255-2262. PMC: 5178827. DOI: 10.1056/NEJMoa1609279. View

20.

Cohen C, Zhao Y, Zheng Z, Rosenberg S, Morgan R . Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006; 66(17):8878-86. PMC: 2147082. DOI: 10.1158/0008-5472.CAN-06-1450. View